Compare TGLS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGLS | REPL |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2011 | 2018 |
| Metric | TGLS | REPL |
|---|---|---|
| Price | $46.64 | $21.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $57.25 | $23.33 |
| AVG Volume (30 Days) | 327.4K | ★ 3.2M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $370,984,000.00 | N/A |
| Revenue This Year | $14.97 | N/A |
| Revenue Next Year | $12.20 | $513.15 |
| P/E Ratio | $27.78 | ★ N/A |
| Revenue Growth | ★ 17.98 | N/A |
| 52 Week Low | $34.05 | $1.50 |
| 52 Week High | $54.85 | $23.64 |
| Indicator | TGLS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 70.94 |
| Support Level | $41.54 | $7.19 |
| Resistance Level | $47.37 | N/A |
| Average True Range (ATR) | 2.06 | 1.67 |
| MACD | 0.66 | 0.42 |
| Stochastic Oscillator | 83.78 | 82.86 |
Tecnoglass Holdings Inc, formerly Tecnoglass Inc, is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.